Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 6/20 | 0.59 |
| ▸ | CDK9 | P50750 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 9/20 | 0.53 |
| ▸ | CA12 | O43570 | 8/20 | 0.53 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
| ▸ | EPM2A | O95278 | 1/20 | 0.44 |
| ▸ | PTPRC | P08575 | 1/20 | 0.44 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.44 |
| ▸ | CDC14A | Q9UNH5 | 1/20 | 0.44 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2605170 | 0.85 | EPM2A (0.53) | DYRK1ACDK9CA2CA12EPM2A | |
| SCHEMBL28031961 | 0.82 | DYRK1A (0.41) | DYRK1ACDK9CA2CA12CHRNB4 | |
| Benzene SCHEMBL29028842 | 0.81 | EPM2A (0.50) | DYRK1ACDK9CA2CA12EPM2A | |
| SCHEMBL15504108 | 0.79 | DYRK1A (0.65) | DYRK1ACDK9CA2CA12CHRNB4 | |
| SCHEMBL1602484 | 0.79 | DYRK1A (0.69) | DYRK1ACDK9CA2CA12CHRNB4 | |
| SCHEMBL27741085 | 0.76 | DYRK1A (0.65) | DYRK1ACDK9CA2CA12CHRNB4 | |
| SCHEMBL28135391 | 0.76 | DYRK1A (0.65) | DYRK1ACDK9CA2CA12CHRNB4 | |
| SCHEMBL1492819 | 0.74 | EPM2A (0.50) | DYRK1ACDK9CA2CA12EPM2A | |
| SCHEMBL6829643 | 0.74 | DYRK1A (1.00) | DYRK1ACDK9CA2CA12CHRNB4 | |
| SCHEMBL28275725 | 0.74 | DYRK1A (0.62) | DYRK1ACDK9CA2CA12CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301268-B2 | Analogs of fexaramine and methods of making and using | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2019-05-28 | — | — | US | disclosed |
| US-20180000768-A1 | INTESTINAL FXR AGONISM ENHANCES GLP-1 SIGNALING TO RESTORE PANCREATIC BETA CELL FUNCTIONS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2018-01-04 | — | — | US | disclosed |
| US-9809602-B2 | Compounds for treating viral infections | INSTITUT PASTEUR KOREA (KR) | 2017-11-07 | — | — | US | disclosed |
| US-20170066724-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170066724-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2017-03-09 | — | — | US | disclosed |
| US-20170044181-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | INSTITUT PASTEUR KOREA (KR) | 2017-02-16 | — | — | US | disclosed |
| US-20170044181-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | INSTITUT PASTEUR KOREA (KR) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180000768-A1 | INTESTINAL FXR AGONISM ENHANCES GLP-1 SIGNALING TO RESTORE PANCREATIC BETA CELL FUNCTIONS | GLP1R, GIPR, FXR1 | DYRK1A 756/4885CDK9 4151/4885CA2 2495/4885 |
| US-20170066724-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | FXR2, FXR1, SLC10A2 | DYRK1A 1655/4885CDK9 4194/4885CA2 1970/4885 |
| US-10301268-B2 | Analogs of fexaramine and methods of making and using | FXR2, FXR1, SLC10A2 | DYRK1A 1655/4885CDK9 4194/4885CA2 1970/4885 |
| US-20170044181-A1 | COMPOUNDS FOR TREATING VIRAL INFECTIONS | HAVCR2, MAVS, EIF2AK2 | DYRK1A 4847/4885CDK9 2103/4885CA2 4347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.